These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8957053)

  • 61. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up.
    Lyne JC; Vivas CA; Shapiro R; Scantlebury VP; Hakala TR; Starzl TE; Jordan ML
    Transplant Proc; 1997; 29(1-2):312. PubMed ID: 9123015
    [No Abstract]   [Full Text] [Related]  

  • 62. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract]   [Full Text] [Related]  

  • 63. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

  • 64. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Diffuse anterior scleritis during OKT3 monoclonal antibody therapy for renal transplant rejection.
    McCarthy JM; Sullivan K; Keown PA; Rollins DT
    Can J Ophthalmol; 1992 Feb; 27(1):22-4. PubMed ID: 1555131
    [TBL] [Abstract][Full Text] [Related]  

  • 66. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.
    Woodle ES; Bluestone JA; Zivin RA; Jolliffe LK; Auger J; Xu D; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1369-70. PubMed ID: 9636555
    [No Abstract]   [Full Text] [Related]  

  • 68. New insights into therapy with monoclonal antibodies in allograft transplantation.
    Schena FP
    Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
    [No Abstract]   [Full Text] [Related]  

  • 69. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
    Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS
    Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203
    [No Abstract]   [Full Text] [Related]  

  • 70. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 71. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols.
    Chkhotua AB; Klein T; Shabtai E; Yussim A; Bar-Nathan N; Shaharabani E; Lustig S; Mor E
    Urology; 2003 Dec; 62(6):1002-6. PubMed ID: 14665344
    [TBL] [Abstract][Full Text] [Related]  

  • 72. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients.
    Kliem V; Schaumann D; Ehlerding G; Eberhard OK; Lufft V; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R
    Transplant Proc; 1997 Nov; 29(7):2955-7. PubMed ID: 9365627
    [No Abstract]   [Full Text] [Related]  

  • 74. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
    Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
    Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.
    Schnitzler MA; Woodward RS; Lowell JA; Singer GG; Brennan DC
    Transplant Proc; 1999 May; 31(3B Suppl):19S-21S. PubMed ID: 10330963
    [No Abstract]   [Full Text] [Related]  

  • 76. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Dec; 10(6 Pt 1):538-41. PubMed ID: 8996775
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

  • 78. Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.
    De Pauw L; Abramowicz D; Goldman M; Vereerstraeten P; Kinnaert P; Toussaint C
    Transplant Proc; 1990 Aug; 22(4):1759-60. PubMed ID: 2117800
    [No Abstract]   [Full Text] [Related]  

  • 79. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts.
    Broyer M; Gagnadoux MF; Guest G; Arsan A; Beurton D; Revillon Y; Niaudet P
    Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.